General Bacteriology 1 and 2. List of samples and the microbes linked to the corresponding photo replies since
|
|
- Clarence Nelson
- 6 years ago
- Views:
Transcription
1 External Quality Assessment Scheme General Bacteriology 1 and 2. List of samples and the microbes linked to the corresponding photo replies since Microbe Survey/ Sample Specimen type. Patient data Photo number Aerobic Gram-Positive Cocci Staphylococci, Micrococci and related bacteria Staphylococcus aureus /2 Skin smear. Eczema. DM. 5 Staphylococcus aureus /9 Pus. Impetigo. 3 and 4 Staphylococcus aureus /16 BAL sample. Neutropenic patient 17,19,20 and 21 Staphylococcus aureus /9 Pus from skin pustule / Pemphi- 2,3 and 4 gus neonatorum Staphylococcus aureus /10 Middle ear effusion 5,6,7 and 9 Staphylococcus aureus /1 Pus from infected surginal wound 1,2,3 Staphylococcus aureus /5 Pus. Skin eczema 6-9,12 Staphylococcus aureus /42 Pus. Conjuctivitis in a child. 7-9 Staphylococcus epidermidis /3 Tissue sample. TEP 9 Staphylococcus epidermidis /8 Pus. Open leg fracture. 12 Staphylococcus epidermidis /3 Tissue sample. Corneal ulcer 10 and 11 Staphylococcus epidermidis /14 Conjuntival sample 6 and 7 Staphylococcus haemolyticum /6 Smear sample behind earflap 6,7,8,9,10 Staphylococcus hominis /14 Pus. Leg ulcer. 6,7 and 9 Staphylococcus hominis /10 Pus- Leg ulcer 6-11,17 Staphylococcus hominis /23 Pus from mandibular fistula 25 Staphylococcus intermedius /31 Dog bite 3-8 Staphylococcus lugdunensis /3 Cardiac pacemaker electrode 16,17,18,19 and 20 Staphylococcus lugdunensis /12 Middle ear effusion Staphylococcus lugdunensis /31 Abscess on a toe 1-7 Staphylococcus warneri /14 Middle ear effusion 5,6,7,12,13 Staphylococcus warneri /16 Venous catheter Staphylococcus warneri /22 Contact lens infection Staphylococcus xylosus /16 Venous catheter 30-32, Coagulase negative staphylococcus /14 Pus. Impetigo. 7,8 and 9 Micrococcus sp /6 Middle ear effusion. 5 and 6 Micrococcus sp /6 Smear sample behind earflap 6,7,8,9,11 Micrococcus sp /12 Middle ear effusion 15 Streptococci, Enterococci and related bacteria /14 Pus. Impetigo. 7,8 and /5 Middle ear effusion. 3,4and /2 Pus Axillary eczema 8,9,10,11 and /1 Pus. Pharyngeal abscess 2,3,4, /12 Pus. Smear sample from skin. 10,11,12,13,14 and 17
2 Beta-hem.streptococcus group B /14 Pus.Leg ulcer. 6,7 and 8 (Streptococcus agalactiae) Beta-hem.streptococcus group B /8 Amnionic fluid 29-32,39-40 (Streptococcus agalactiae) Beta-hem.streptococcus group C (Streptococcus dysgalactiae ssp /11 Pus. Abscess. 16,17,18,19,20 21,22 equisimilis) Beta-hem.streptococcus group F (Streptococcus anginosus) /16 Pus. Pulmonal empyema 21,22,23,24,25 26 Beta-hem.streptococcus group G / 1 Pus. Peritonsillary abscess 3 Beta-hem.streptococcus group G /6 Pus. Groin abscess. 6,7,8 and 9 Beta-hem.streptococcus group G /10 Pus. Leg ulcer 5-13 Enterococcus faecalis Bile specimen 19-20, Enterococcus faecium /4 Pus. Groin abscess. 14,15,16 and 17 Enterococcus faecium /33 Pus from pelvic abscess 29-31,35-36 Enterococcus casseliflavus /7 Tip of venous catether 13,14,15,16,17 Leuconostoc sp /32 Leg ulcer 10-14, /5 Cerebrospinal fluid /1 Pus. Maxillay sinusitis /13 Cerebrospinal fluid. Meningitis 3 and /14 Middle ear effusion 6,7,8,9,10, /9 Middle ear effusion 2,3, /12 Middle ear effusion /41 Middle ear effusion 2-5 Streptococcus viridans /7 Pus Abscess 14 and 15 Streptococcus viridans /14 Conjuctival sample 6 and 7 Streptococcus viridans /15 Pus. Frontal sinusitis. 10 and 28 Streptococcus viridans /14 Middle ear effusion 6,7,8,9,11 Streptococcus viridans /32 Maxillary sinus excretion 8-12,16 Streptococcus viridans /34 Pleural empyema 28-31,33-41 Streptococcus anginosus /15 Aortic valve. Endocarditis Streptococcus anginosus /16 Pus. Pulmonal empyema 21,22,23,24,25 26 Streptococcus parasanguis /11 Cardiac valve. Endocarditis 15,16 and 17 Aerobic Gram-Positive Bacilli Actinomadura madurae /3 Tissue specimen. Leg ulcer Arcanobacterium haemolyticum /2 Purulent maxillary sinus excretion 5,6,7,8,9,10,11 Arcanobacterium haemolyticum /32 Maxillary sinus excretion 8-15 Bacillus cereus /3 Tissue sample. Corneal ulcer 10,11 and 12 Bacillus cereus /6 Smear sample behind earflap 6,7,8,9,12 Bacillus megaterium /12 Pus, Smear sample from skin 10-16,21 Corynebacterium sp.(diphtheroid) /2 Skin smear. Eczema. DM. 5 and 7 Corynebacterium sp.(diphtheroid) /6 Middle ear effusion 5 and 6 Corynebacterium jeikeum /10 Pus. Leg burn 7,8,9,10,14,15 Corynebacterium jeikeum /13 Tissue specimen Corynebacterium ulcerans /11 Troat specimens Corynebacterium urealyticum /7 Pus. Obstructed urether 12,13,14,15 and 16 Dermabacter hominis /24 Smear sample from nipple spearcing Listeria monocytogenes /16 Amnionic fluid 30,31,32,33,34 35
3 Listeria monocytogenes /11 Smear sample from placenta 3,4,5,6,7,8 Rhodococcus equi /12 Sputum sample/ An immunocompromized patient 25,26,27,28 and 29 Aerobic Gram-Negativive Cocci Moraxella catarrhalis /6 Middle ear effusion 5 and 6 Moraxella catarrhalis /9 Middle ear effusion 3 and 4 Moraxella catarrhalis /10 Middle ear effusion 5,6,7 and 9 Moraxella catarrhalis /14 Middle ear effusion 6-12 Neisseria gonorrhoeae /13 Synovial fluid 3,4 and 5 Neisseria gonorrhoeae /8 Pus from infected big toe 18,19,20,21,22 Neisseria gonorrhoeae /1 Pus from uterine cavity 3,4,5,6 Neisseria menigitidis /2 Pus. Maxillary sinusitis 6-8,12-13 Neiseria mucosa /2 Purulent maxillary sinus excretion 5,6,7,14,15 Neisseria sicca /32 Maxillary sinus excretion 8-12,17-18 Aerobic Gram-Negative Bacilli Fermentative rods Acinetobacter baumannii /16 Cerebrospinal fluid. 14,15,16 and 17 Acinetobacter baumannii /14 Conjunctival sample. 6,7,8,9 and 10 Aeromonas hydrophila /8 Pus. Open leg fractura. 12 Citrobactrer koseri (C diversus) /12 Ascites fluid Citrobacter werkmanii /44 Pus from gall bladder 29-32,33-34,37 Cronobacter sakazakii See Enterobacter sakazakii Enterobacter aerogenes /3 Bile specimen Enterobacter cloacae /16 Cerebrospinal fluid. 14,15,16 and 17 Enterobacter cloacae /16 Bal sample. Neutropenic patient 17,22 and 23 Enterobacter cloacae /14 Tissue. Leg ulcer Enterobacter (Cronobacter) sakazaii /3 Ascites fluid. Traffic accident. 16,17,18,19,20 21,27,28,31,37 Escherichia coli /12 Ascites fluid 14 Escherichia coli /8 Ascites fluid 20 and 21 Escherichia coli /3 Ascites fluid. Traffic accident. 16,17,18,19,20 21,24,25,26,31 Escherichia coli /6 Pus. Skin eczema 6-9,13-15 Escherichia coli, CPE /11 Wound 3-5 Hafnia alvei /14 Tissue. Leg ulcer ,43-45 Klebsiella oxytoca /15 Pus from snake bite Klebsiella pneumoniae /1 Pus. Leg fractura. 3,4,5 and 6 Klebsiella pneumoniae /11 Pus. Ovarial abscess 11,12,13,14,15 16,18 and 19 Klebsiella pneumoniae /5 Pus from pancreatic drainage 2,3,4,5 Klebsiella pneumoniae ssp rhinoscleromtis /2 Maxillary sinus excretion 7-13 Ochrobactrum anthropi /11 Pus. Abscess. 16,17,18,19,20 24,25,26,27 Morganella morgnii /33 Pus frompelvic abscess Proteus mirabilis /2 External ear canal effusion 5,6 and 7 Proteus vulgaris /8 Pus. Cholecystitis. 18,19,20,22,23 and 26 Proteus vulgaris /15 Pus from snake bite 13-17, Rahnella aquatilis /43 Pus. Wound. Fish farming 13-19, Salmonella sp /3 Ascites fluid. Traffic accident ,24,29-31 Salmonella sp. (S Enteritidis) /44 Pus from gall bladder 29-32, Serratia fonticola /12 Ascites fluid 14 Serratia fonticola /32 Leg ulcer Serratia rubidaea /8 Pus. Cholecystitis. 18,19,20,24,25 and 25
4 Nonfermentative rods Achromobacter denitrificans /6 Skin eruption. Groin. 6,7,9,10 11 and 12 Achromobacter xylosoxidans /22 Contact lens infection 8-14 Chryseomonas meningoseptica. Kts. Elizabethkingia meningoseptica Elizabethkingia meningoseptica /10 Pus. Maxillary sinusitis. 6,7,8,10,11,12 13 and 23 Pasteurella multocida /4 Tissue sample. Dog bite. 33,34,35,36 Pasteurella multocida /13 Tissue sample. Animal bite. 2,3,4,5 Pasteurella multocida /13 Pus from cheek abscess. Cat bite. 23,24,25,26 Pseudomonas aeruginosa /7 Ascites fluid. 8 Pseudomonas aeruginosa /13 Sputum. Cystic fibrosis 3 and 4 Pseudomonas aeruginosa /9 External ear canal exudate 2,3,4,5 and 6 Pseudomonas aeruginosa /10 Pus. Leg ulcer 6-11,13-16 Pseudomonas oryzihabitans /2 Pus, Maxillary sinus excretion. 8-10,14-16 Pseudomonas stutzeri /12 Pus. Smear sample from skin 10-16, Ralstonia pickettii /6 Aqua destillata 6,7,8,9 and 10 Sphingobacterium multiforum /12 Skin wound. 19,20,21,22 and 23 Stenotrophomonas maltophilia /8 Pus. Open leg fractura. 12 Stenotrophomonas maltophilia /10 Pus. Leg burn 7-13 Vibrio parahaemolyticus /43 Pus. Wound. Fish farming, Haemophilus strains Haemophilus influenzae /10 Pus. Maxillary sinusitis 9 Haemophilus influenzae /5 Pus. Maxillary sinusitis 3 and 4 Haemophilus influenzae /10 Middle ear effusion 5,6,7 and 8 Haemophilus influenzae /2 Pus. Maxillary sinusitis 6-11 Haemophilus influenzae /5 Pus. Maxillary sinusitis 2-5 Haemophilus influenzae /13 Middle ear effusion 2-5 Haemophilus influenzae /21 Pus. Maxillary sinusitis 3-6 Haemophilus parainfluenzae /2 Purulent maxillary sinus excretion 5,6,7,12,13 Haemophilus parainfluenzae /42 Pus. Conjunctivitis in a child 7-12 Other Gram-Negative Bacilli and Vibrios Actinobacillus actinomycetemcomitans kts. Aggregatibacter actinom. Aggregatibacter actinomycetemcomitans /7 Pus Abscess 14,15,16,17 and 18 Capnocytophaga canimorsus /4 Wound. Dog bite Cardiobacterium hominis /33 A piece of cardiac valve Eikenella corrodens /23 Pus from mandibular fistula Vibrio vulnificus /10 Skin wound. Sushi bar keeper. 6,7 and 8 Anaerobic Gram-Positive Cocci Finegoldia magna /16 Pus. Pulmonal empyema. 21,27,28,29,30 31,32,33,34,39 40,41,42 Finegoldia magna /4 Pus. Brain abscess 26,31-34,41-44 Peptostreptococcus anaerobius /4 Pus. Groin abscess. 17,18,19,22,23 and 24 Peptostreptococcus anaerobius /8 Amnionic fluid 29-30,31-37,41-44 Staphylococcus saccharolyticus /14 Tissue specimen lumbar vertebra Anaerobic Gram-Positive Bacilli Actinomyces israelii /11 Pus. Ovarial abscess 11-17, Actinomyces mayeri /34 Pleural empyema Actinomyces naeslundi /4 Pus. Brain abscess. 11,12 and 13 Actinomyces odontolyticus /4 Pus. Brain abscess 26,34,38-41 Clostridium innocuum /4 Pus. Liver abscess. 22,23,24,25,26 and 27
5 Clostridium innocuum /13 Tissue specimen Clostridium ramosum /44 Pus from gall bladder Clostridium septicum /15 Pus from snake bite Clostridium perfringens /33 Pus from pelvic abscess Clostridium sporogenes /8 Ascites fluid. 21,22,23,25,26 28 and 29 Clostridium sporogenes /12 Ascites fluid 28-29,44-46 Clostridium tertium /7 Myonecrosis. Tissue specimen Eggerthella lenta /8 Amnionic fluid 29-30,33-37,45-48 Propionibacter acnes /15 Skin smear sample around a cystofix catheter 12,13,14 and 15 Propionibacter acnes /8 Pus from infected big toe 18,23,24,25,26 Propionibacter acnes /24 Smear sample from nipple spearcing Anaerobic Gram-Negative Bacilli Bacteroides fragilis /7 Ascites fluid 9 Bacteroides fragilis /4 Pus. Groin abscess 17,18,19,20,21 23 and 24 Bacteroides fragilis /8 Pus. Cholecystitis. 21,27,28 and 29 Bacteroides fragilis /14 Tissue specimen. Leg ulcer Bacteroides ovatus /12 Ascites fluid 28-29,35-43 Bacteroides thetaiotamicron /12 Ascites fluid 15 and 16 Bacteroides vulgatus /11 Pus. Abscess. 16,28,29,30,31 32 Bacteroides vulgatus /3 Bile specimen 19-20, Fusobacterium necrophorum /15 Pus. Frontal sinusitis. 12,13,14,16 18,19,20,21,22 Fusobacterium nucleatum /16 Pus. Pulmonal empyema. 21,27,28,29,30 31,32,33,34 35,36,37,38 Fusobacterium nucleatum /34 Pus taken by bronchoscopy 44-48,53-55 Fusobacterium russii /13 Pus from cheek abscess. Cat bite Prevotella disiens /8 Ascites fluid 21,22,24,25,27 28 and 29 Prevotella melanogenica /4 Pus. Brain abscess. 11,12 and 13 Prevotella melanogenica /15 Pus. Frontal sinusitis. 12,13,14,15,23 24,25,26,27 Prevotella melanogenica /34 Pus taken by bronchoscopy Mycobacteria Mycobacterium abscessus /11 Tissue sample. Corneal ulcer. 10 and 11 Mycobacterium abscessus /15 Tissue sample. Arm ulcer. 13,14,15,16,17 18,19,20 Yeasts and Molds Candida albicans /2 Skin smear. Eczema. DM. 5,6,7 Candida albicans /7 Ascites fluid 10 Candida albicans /2 Pus Axillary eczema 8,9,10,13 and 14 Candida albicans /6 Pus. Skin eczema 6-10,16-17 Candida glabrata /16 Bal sample. Neutropenic patient 17,18,24 and 25 Candida glabrata /32 Leg ulcer 10-14,24-26 Aspergillus fumigatus /2 External ear canal effusion 5 and 8 Information Yvonne Björkman yvonne.bjorkman@labquality.fi
6 Labquality Ratamestarinkatu 11 FI Helsinki FINLAND Telephone Fax info@labquality.fi Labquality
General Bacteriology 1 (5080) and 2 (5081). List of microbes included in the specimens linked to the corresponding photo replies since
External Quality Assessment Scheme General Bacteriology 1 (5080) and 2 (5081). List of microbes included in the specimens linked to the corresponding photo replies since 1.1.2008. Microbe Round/ Specimen
More informationSUPPLEMENTARY MATERIAL
SUPPLEMENTARY MATERIAL (A) Further inclusion criteria and categorisation of ICD-10 diagnostic codes Pneumonia: A310 Pulmonary mycobacterial infection A420 Pulmonary actinomycosis A481 Legionnaires' disease
More informationNational Surveillance of Nosocomial Septicemia (Hospital-wide)
National Surveillance of Hospital Infections National Surveillance of Nosocomial Septicemia (Hospital-wide) National analysis Data from 01/01/2008 to 31/12/2008 1. SUMMARY BY QUARTER Quarter Patient records
More informationSupplemental Digital Content
Rapid Diagnosis of Infection in the Critically Ill (RADICAL), a multicenter study of molecular detection in bloodstream infections, pneumonia and sterile site infections Jean-Louis Vincent, David Brealey,
More informationReceived 1 March 2011/Returned for modification 19 April 2011/Accepted 20 May 2011
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2011, p. 2980 2984 Vol. 49, No. 8 0095-1137/11/$12.00 doi:10.1128/jcm.00431-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Utility of
More informationZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg
ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationLabquality External Quality Assessment Programmes General Bacteriology 1 3/2014
Labquality External Quality Assessment Programmes General Bacteriology 1 3/2014 Photos and text: Markku Koskela, M.D., Ph.D. Clinical microbiology specialist Nordlab Oulu, Finland Specimen 31/2014 Abscess
More informationMicrosan rx Anti-Microbial Healthcare Professional Soap. Organism Positives ATCC #
: Contact Time: 30 seconds 17,500 ppm. PCMX active Organism Positives ATCC # Acinetobacter calcoaceticus var. anitratus 0 s Acinetobacter calcoaceticus var. woffii 0 s Actinobacillus pleuropneumonia 0
More informationINTRA-ABDOMINAL INFECTIONS - II
William J. Brown, Ph.D. Page 1 of 8 September 21, 2001 (Gastrointestinal Infections VI) INTRA-ABDOMINAL INFECTIONS - II PERITONITIS AND ABSCESSES I. PERITONITIS II. INTRAPERITONEAL ABSCESS III. VISCERAL
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationCeftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection)
COMPOSITION Ceftomax TM S (Cefoperazone Sodium plus Sulbactam Sodium Injection) CEFTOMAX - S Injection 1.5 gm Each vial contains: Cefoperazone Sodium equivalent to Cefoperazone IP. 1,000 mg Sulbactam Sodium
More informationLabquality External Quality Assessment Programmes General Bacteriology 1 3/2013
Labquality External Quality Assessment Programmes General Bacteriology 1 3/2013 Photos and text: Markku Koskela, M.D., Ph.D. Clinical microbiology specialist Oulu, Finland Sample 21/2013 Maxillary sinus
More informationDIVISION OF ANTIINFECTIVE DRUG PRODUCTS (HFD-520) CLINICAL MICROBIOLOGY REVIEW NDA Date review completed: 15 Jun 05
Date company submitted: 15 Dec 04 Date received by CDER: 15 Dec 04 Reviewer: Fred Marsik, Ph.D. Date assigned: 15 Dec 04 NAME AND ADDRESS OF APPLICANT Wyeth Pharmaceuticals Inc. P.O. Box 8299 Philadelphia,
More informationBrief Communication Clinical Microbiology
Brief Communication Clinical Microbiology Ann Lab Med 2017;37:531-535 https://doi.org/10.3343/alm.2017.37.6.531 ISSN 2234-3806 eissn 2234-3814 Comparison of a New Matrix-Assisted Laser Desorption/Ionization
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationUniversity of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology
University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational
More informationM O L E C U L A R G E N E T I C S
MOLECULAR GENETICS ADVANTAGES OF MOLECULAR GENETICS Molecular genetics is a dynamic and transformative area of diagnostics, leading to insights in research and treatment in many disease states that are
More informationBACTERIOLOGY PROGRAMME AND PLAN OF TEACHING 3 rd Semester (academic year )
BACTERIOLOGY PROGRAMME AND PLAN OF TEACHING 3 rd Semester (academic year 2012-2013) 19. 10. 2012. Introduction in microbiology, bacterial taxonomy, general bacterial prop Bacterial structures, biosynthesis
More informationCell counting (EtBr) Before cell-lysis. Cell-lysis by 3% SDS beads beating. After cell-lysis
Key words Sample Cell counting (EtBr) DNA extraction Cell-lysis by 3% SDS beads beating Before cell-lysis After cell-lysis Cell-lysis efficiency (Maintained70%) PCR PCR amplification of partial fragments
More informationNormal Human Flora. (Human Microbiome) Dr.Sarmad M.H. Zeiny Baghdad College of Medicine
Normal Human Flora (Human Microbiome) Dr.Sarmad M.H. Zeiny Baghdad College of Medicine 2014-2015 Objectives Describe important human normal flora. Demonstrate the epidemiology of human normal flora. Determine
More informationComparative study of MALDI-TOF MS and VITEK 2 in bacteria identification
MALDI-TOF MS in Clinical Microbiology Comparative study of MALDI-TOF MS and VITEK 2 in bacteria identification Ling Guo, Liyan Ye, Qiang Zhao, Yanning Ma, Jiyong Yang, Yanping Luo Department of Microbiology,
More informationSurveillance of Healthcare Associated Infections in Scottish Intensive Care Units
Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January 2010 to December 2010 Scottish Intensive Care Society Audit Group 1 Health Protection
More informationOptimizing MALDI-TOF Use. Clinical Impact Laboratory Impact
Optimizing MALDI-TOF Use Clinical Impact Laboratory Impact Christine C. Ginocchio, PhD, MT (ASCP) Clinical Professor of Medicine Hofstra North Shore-LIJ School of Medicine, NY VP, Global Microbiology Affairs,
More informationKENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #
Inc. Efficacy: Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic serum
More informationHYPOCHLOROUS ACID (HOCl) Our Body's immune system protector in a BOTTLE
AQUAOX IS A REVOLUTIONARY DISINFECTION SOLUTION WHICH ACTIVE INGREDIENT HOCL IS NON HAZARDOUS, HAS NO FRAGRANCE, AND IS SAFE ON ALL SURFACES (AND ON SKIN.) HYPOCHLOROUS ACID (HOCl) Our Body's immune system
More informationYes No Unknown. In hospital Out of hospital Unknown. Blood Pump Drive Unit Failure External Control System Failure. Yes No Unknown
Adverse Events Device Malfunction Was there a device malfunction: Date of event: Was there a device malfunction: Major pump unit involved: Check all the apply Suspected device Thrombosis: Anticoagulant
More informationThis material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.
Division of Medical Microbiology Department of Laboratory Medicine and Pathology University of Alberta Hospital and Stollery Children's Hospital Antibiogram 2006 This material is supported in part by unrestricted
More informationLabquality External Quality Assessment Programmes General Bacteriology 1 2/2013
Labquality External Quality Assessment Programmes General Bacteriology 1 2/2013 Photos and text: Markku Koskela, M.D., Ph.D. Clinical microbiology specialist Oulu, Finland Sample 11/2013 Pus sample from
More informationStreptococci facultative anaerobe
THE GENUS STREPTOCOCCUS The genus Streptococcus obtains Gram-positive cocci, nonmotile, nonsporeforming, arranged mostly in chains or in pairs. Most species are facultative anaerobes. Some of streptococci
More informationINFECTIOUS DISEASE. Page 2
Infectious disease Advantages OF TESTING INFECTIOUS DISEASE We are in the middle of a paradigm shift in infectious disease diagnostic testing. As we move from targeted infectious disease testing to a syndromic
More informationIMIPENEM CILASTATIN SODIUM
IPC-TEN-IV/IM-082009 PHYSICIANS CIRCULAR IMIPENEM CILASTATIN SODIUM TIENAM Powder for I.V. Infusion Antibacterial IMIPENEM and CILASTATIN SODIUM (TIENAM ) is a broad spectrum beta-lactam antibiotic supplied
More informationKENNEL KARE SC DISINFECTANT / CLEANER / DEODORIZER Efficacy Data EPA Reg. #
Inc. Efficacy: Hospital Disinfection (at ½ ounce per gallon) Kennel Kare SC is bactericidal according to the AOAC Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic
More informationVITEK MS Implementation of Mass Spectrometry
VITEK MS Implementation of Mass Spectrometry Willson Jang, Technical Leader wljang@providencehealth.bc.ca Microbiology & Virology Laboratory Providence Health Care St. Paul s Hospital October 23, 2013
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory CEFTUM TABLETS. Cefuroxime Axetil Tablets IP 125/250/500mg
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CEFTUM TABLETS Cefuroxime Axetil Tablets IP 125/250/500mg QUALITATIVE AND QUANTITATIVE COMPOSITION CEFTUM TABLETS 125
More informationSurveillance of Healthcare Associated Infections in Scottish Intensive Care Units
Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January - December 2012 Scottish Intensive Care Society Audit Group Health Protection Scotland
More informationLabquality External Quality Assesment Programmes General Bacteriology 1 1/2010
Labquality External Quality Assesment Programmes General Bacteriology 1 1/2010 Photos and text: Markku Koskela, M.D., Ph.D. Clinical microbiology specialist Oulu, Finland Sample 1/2010 Pus from an infected
More informationSep Oct Nov Dec Total
LB PAGE 2 LB PAGE 3 Sep Oct Nov Dec 2007 2007 2007 2007 Total Repeat Information Total Repeats 35 15 17 9 76 Repeat Rate 6.01% 0.17% 1.12% 0.39% 2.07% Repeat Chemistry 25 0 2 0 27 Repeat Extraction 1 0
More informationPrimaxin IV Injection
Seite 1 von 20 Merck Sharp & Dohme Limited Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU Telephone: +44 (0)1992 467 272 Fax: +44 (0)1992 452 206 Medical Information e-mail: medicalinformationuk@merck.com
More informationMINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS. Patient Information Leaflet
No. 851 of August 19, 2014 КЛС No. 10 of July 31, 2014 Invented trade name: Cefosulbactam MINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS Patient Information Leaflet CEFOSULBACTAM (ЦЕФОСУЛЬБАКТАМ) Powder
More informationSurveillance of Healthcare Associated Infections in Scottish Intensive Care Units
Surveillance of Healthcare Associated Infections in Scottish Intensive Care Units Annual report of data from January 2011 to December 2011 Scottish Intensive Care Society Audit Group Health Protection
More informationOverview of Tigecycline and Its Role in the Era of Antibiotic Resistance
BJID 2006; 10 (June) 203 Overview of Tigecycline and Its Role in the Era of Antibiotic Resistance Flávia Rossi, Denise Andreazzi University of São Paulo, LIM 03; São Paulo, SP, Brazil The increasing antimicrobial
More informationM E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 7 Microbiology 2017 MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Evaluation Criteria... 2 Microbiology
More informationEfficacy Data. Disinfectant Cleaner & Odor Counteractant EPA REG. #
SENTS-ALE Hospital Disinfection (at 2 ounces per gallon)) Scents-Able is bactericidal according to the AOA Use Dilution Test method on hard inanimate surfaces modified in the presence of 5% organic serum
More informationIn the absence of underlying edema or other skin abnormalities, erysipelas
ERYSIPELAS Erysipelas is a distinct type of superficial cutaneous cellulitis with marked dermal lymphatic vessel involvement caused by group A β-hemolytic streptococcus (very uncommonly group C or G streptococcus)
More informationMERREM IV. meropenem PRODUCT INFORMATION COOH CH 3
MERREM IV meropenem PRODUCT INFORMATION NAME OF THE DRUG Meropenem, as meropenem trihydrate. DESCRIPTION Structural Formula: HO H 3 C O COOH H N S H H H H CH 3 H NH CON(CH 3 ) 2. 3H2 O CAS Number: 119478-56-7
More informationClass 15. Infections of the Central Nervous System
English Division 6 E.D. Class 15 Infections of the Central Nervous System Pathogenesis, etiologic agents, clinical symptoms, and laboratory diagnosis To be performed: - Read carefully attached case studies
More informationUtility of Gram stain in the clinical management of suspected ventilator-associated pneumonia Secondary analysis of a multicenter randomized trial
Journal of Critical Care (2008) 23, 74 81 Utility of Gram stain in the clinical management of suspected ventilator-associated pneumonia Secondary analysis of a multicenter randomized trial M. Albert MD
More informationFAROBACT 200 Tablets (Faropenem)
Published on: 10 Jul 2014 FAROBACT Tablets (Faropenem) Composition FAROBACT Tablets Each film-coated tablet contains: Faropenem Sodium equivalent to Faropenem... Dosage Form Oral tablet Pharmacology Pharmacodynamics
More informationM E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 8 Microbiology 2018 MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Evaluation Criteria... 2 Microbiology
More informationOn-demand diagnosis of TB and rifampinresistance using the Xpert MTB/RIF assay: the present and the future.
On-demand diagnosis of TB and rifampinresistance using the Xpert MTB/RIF assay: the present and the future. David Alland, MD Chief, Division of Infectious Diseases New Jersey Medical School-UMDNJ Newark,
More informationRandomized Prospective Study Comparing Moxalactam and Cefoxitin with or without Tobramycin for the Treatment of Serious Surgical Infections
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1986, p. 244-249 0066-4804/86/020244-06$02.00/0 Copyright C 1986, American Society for Microbiology Vol. 29, No. 2 Randomized Prospective Study Comparing Moxalactam
More informationBio Microbiology - Spring 2013 Study Guide 20 Normal Flora - Normal Responses - Disease
Bio 230 - Microbiology - Spring 2013 Study Guide 20 Normal Flora - Normal Responses - Disease It has been calculated that the normal human houses about 10 12 bacteria on the skin, 10 10 in the mouth, and
More informationClinical and Microbiological Evaluation of Osteomyelitis
Bahrain Medical Bulletin, Vol.23, No.2, June 2001 Clinical and Microbiological Evaluation of Osteomyelitis Haider Abdul-Lateef Mousa, MBChB, MSc* Thamer A Hamdan, MBChB, FRCS** Sundus S Bakr, BSc, PhD***
More informationMALDI-TOF mass spectrometry for direct bacterial identification
JCM Accepts, published online ahead of print on 17 February 2010 J. Clin. Microbiol. doi:10.1128/jcm.01780-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All
More information12/12/2011. Atypical Pneumonia. Objectives. Causative Agents of Acute Pneumonia Bacteria. Causative Agents of Acute Pneumonia Other Agents
Objectives Atypical Pneumonia K. Sue Kehl, Ph.D., D(ABMM) Associate Professor, Pathology Medical College of Wisconsin Associate Director of Clinical Pathology & Technical Director of Microbiology, Children's
More information1430 West McCoy Lane Santa Maria, CA p:
091217TR HardyCHROM BluEcoli 1 HardyCHROM Candida 2 HardyCHROM ECC 3 HardyCHROM ESBL 4 HardyCHROM Listeria 5 HardyCHROM MRSA 6 HardyCHROM O157 7 HardyCHROM Salmonella 8 HardyCHROM SS NoPRO 9 HardyCHROM
More informationIMMUVIEW S. PNEUMONIAE ANTIGEN TEST. Lateral flow test for qualitative detection of S. pneumoniae in urine and cerebrospinal fluid.
IMMUVIEW S. PNEUMONIAE ANTIGEN TEST Lateral flow test for qualitative detection of S. pneumoniae in urine and cerebrospinal fluid. 2 IMMUVIEW S. PNEUMONIAE ANTIGEN TEST For in vitro diagnostic use Application
More informationISF criteria (International sepsis forum consensus conference of infection in the ICU) Secondary peritonitis
Appendix with supplementary material. This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Supplementary Tables Table S1. Definitions
More informationOsteomyelitis and septic arthritis. Osteomyelitida. Cierny- Mader (1) Bone anatomy. Cierny- Mader (2) Pathogenesis (1)
Osteomyelitis and septic arthritis M A R E K Š TEFAN ID UNIT, MILITAR Y UNIVERSITY HOSPITAL P R A G U E Bone infection Osteomyelitida Inflammatorydestructionof the bone with resultant necrosis Bone anatomy
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Summary of Product Characteristics Meronem I.V. 1g Powder for solution for injection or infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains meropenem
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Meroponia 1g Powder for Solution for Injection or Infusion Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains meropenem trihydrate
More informationCardiovascular Diseases. Dr. Hala Al- Daghistani
Cardiovascular Diseases Dr. Hala Al- Daghistani Cardiovascular system (circulatory system), defined as a group of organs that transport blood, nutrients, and remove waste products it carries to and from
More informationClient Services Manual
Diagnostic Innovation Improving Health Client Services Manual [ Revised 12.21.18 ] Table of Contents About / Instructions Directory... 2 About Diatherix... 3 Specimen Preparation Instructions... 4 Packaging
More informationBacteriologic Findings Associated with Chronic Bacterial Maxillary Sinusitis in Adults
MAJOR ARTICLE Bacteriologic Findings Associated with Chronic Bacterial Maxillary Sinusitis in Adults S. M. Finegold, 1 M. J. Flynn, 1 F. V. Rose, 2 H. Jousimies-Somer, 1 C. Jakielaszek, 2 M. McTeague,
More informationVancomycin Rationale for the EUCAST clinical breakpoints, version June 2010
Vancomycin Rationale for the EUCAST clinical breakpoints, version 2.1 17 June 2010 Introduction The glycopeptides are a class of agents composed of amino acid residues and attached sugars. Glycopeptides
More informationTHE KENYA POLYTECHNIC UNIVERSITY COLLEGE
THE KENYA POLYTECHNIC UNIVERSITY COLLEGE SCHOOL OF HEALTH SCIENCES AND TECHNOLOGY DEPARTMENT OF BIOMEDICAL LABORATORY SCIENCES AND TECHNOLOGY DIPLOMA IN MEDICAL LABORATORY SCIENCES FINAL YEAR EXAMINATION
More informationKOMAR UNIVERSITY OF SCIENCE AND TECHNOLOGY (KUST) Medical Bacteriology Syllabus (Theory) Spring 2016
Course Title Medical Bacteriology Syllabus (Theory) Spring 2016 Medical Bacteriology Course Code MLS3330 No. of Credits Department Medical Laboratory Science (MLS) College Science Pre-requisites Course
More informationS. Q. van Veen,* E. C. J. Claas, and Ed J. Kuijper. Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2010, p. 900 907 Vol. 48, No. 3 0095-1137/10/$12.00 doi:10.1128/jcm.02071-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. High-Throughput
More informationID of Most Common Bacterial Pathogens. CLS 417- Clinical Practice in Microbiology Miss Zeina Alkudmani
ID of Most Common Bacterial Pathogens CLS 417- Clinical Practice in Microbiology Miss Zeina Alkudmani BACTERIA Gram Positive Gram Negative Cocci Bacilli Bacilli Cocci Coccobacilli - Staph - Strept - Clostridium
More informationWound Microbiology and Associated Approaches to Wound Management
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2001, p. 244 269 Vol. 14, No. 2 0893-8512/01/$04.00 0 DOI: 10.1128/CMR.14.2.244 269.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Wound
More informationVOLOXAL. Composition each tablet contains levofloxacin 500 & 750 mg
VOLOXAL Composition each tablet contains levofloxacin 500 & 750 mg Tablets Action Bactericidal; as a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-gyrase complex and topoisomerase IV
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory AUGMENTIN 625 / 1000 DUO
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory AUGMENTIN 625 / 1000 DUO Amoxycillin and Potassium Clavulanate Tablets IP QUALITATIVE AND QUANTITATIVE COMPOSITION AUGMENTIN
More informationSuperbugs in Dental Practice: A Narrative Review
Anushka Gupta, Nagesh Lakshminarayan REVIEW ARTICLE 10.00/jpjournals... 1 Anushka Gupta, 2 Nagesh Lakshminarayan ABSTRACT Microbes do undergo perpetual mutations, thus they evolve swiftly. This may have
More informationCefuroxime sodium equivalent to Cefuroxime 250 mg, 750 mg and 1.5 g Powder for Injection
Cefuroxime-AFT Cefuroxime sodium equivalent to Cefuroxime 250 mg, 750 mg and 1.5 g Powder for Injection Presentation CEFUROXIME-AFT 250 mg contains Cefuroxime sodium equivalent to Cefuroxime 250 mg. CEFUROXIME-AFT
More informationAXITAB-CV TAB. COMPOSITION :
AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil
More informationDiscrepancies in the recovery of bacteria from multiple sinuses in acute and chronic sinusitis
Journal of Medical Microbiology (2004), 53, 879 885 DOI 10.1099/jmm.0.45655-0 Short Communication Correspondence Itzhak Brook ib6@georgetown.edu Received 1 March 2004 Accepted 18 May 2004 Discrepancies
More informationCefuroxime (as sodium)
Cefuroxime (as sodium) Zinacef Powder for Injection Antibacterial PRODUCT DESCRIPTION Cefuroxime (as sodium) (Zinacef ) 250mg Powder for Injection: Each white to faintly yellow powder to which appropriate
More informationZOSUL Injection (Cefoperazone Sodium + Sulbactam Sodium) Cefoperazone Sodium Plus Sulbactam Sodium Injection Zosul
Published on: 10 Jul 2014 ZOSUL Injection (Cefoperazone Sodium + Sulbactam Sodium) Cefoperazone Sodium Plus Sulbactam Sodium Injection Zosul Composition ZOSUL Injection 1.0 g Each vial contains: Cefoperazone
More informationQuality Control Strains
Quality Control Strains Commercial firms specify ATCC strains as controls for rapid identification, minimum inhibitory concentration of antibiotics and antibiotic susceptibility panels. Species and strains
More informationMAGNEX Injection (Sulbactam Sodium/Cefoperazone Sodium 1:1)
MAGNEX Injection (Sulbactam Sodium/Cefoperazone Sodium 1:1) 1. NAME OF MEDICINAL PRODUCT MAGNEX 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Sulbactam sodium/cefoperazone sodium combination is available
More informationCIPLOX-D Eye Drops (Ciprofloxacin 0.3% + Dexamethasone 0.1%)
Published on: 10 Jul 2014 CIPLOX-D Eye Drops (Ciprofloxacin 0.3% + 0.1%) Composition Ciprofloxacin USP...0.3% w/v sodium phosphate IP...0.1% w/v Equivalent to Dosage Form Ophthalmic solution Pharmacology
More informationCEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml. Rx Only
CEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml Rx Only To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial
More informationCEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml. Rx only
CEFPROZIL FOR ORAL SUSPENSION USP 125 mg/5 ml and 250 mg/5 ml Rx only To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial
More informationTigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
Diagnostic Microbiology and Infectious Disease 52 (2005) 181 186 www.elsevier.com/locate/diagmicrobio Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
More informationObjective: To assess the incidence of healthcare-associated infections (HAI) and the prevalence
Abstract Objective: To assess the incidence of healthcare-associated infections (HAI) and the prevalence of pathogens across all pediatric units within a single hospital, and trends in pediatric HAI over
More informationAntimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2005, p. 3501 3512 Vol. 49, No. 8 0066-4804/05/$08.00 0 doi:10.1128/aac.49.8.3501 3512.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationAntibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
More informationPHYSICIANS CIRCULAR. Tablets NOROXIN (norfloxacin, USP)
PHYSICIANS CIRCULAR Tablets NOROXIN is a quinolone carboxylic acid antibacterial agent for oral administration. MICROBIOLOGY NOROXIN has a broad spectrum of antibacterial activity against gram-positive
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationHUSRES Annual Report 2009 Martti Vaara
HUSRES Annual Report 2009 Martti Vaara www.huslab.fi www.intra.hus.fi Martti Vaara, 2/2010 1 The basis of this HUSRES 2009 report is the HUSLAB/Whonet database 2009, which contains susceptibility data
More informationCefuroxime (as sodium)
Cefuroxime (as sodium) Zinacef Powder for Injection Antibacterial PRODUCT DESCRIPTION Cefuroxime (as sodium) (Zinacef ) 250mg Powder for Injection: Each white to faintly yellow powder to which appropriate
More informationInfection Data: Form Updates
Infection Data: Form Updates Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Why is infection data important?
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory AUGMENTIN DDS
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory AUGMENTIN DDS Amoxycillin and Potassium Clavulanate Oral Suspension IP QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5
More informationBabak Valizadeh, DCLS
Laboratory Diagnosis of Bacterial Infections of the Respiratory Tract Babak Valizadeh, DCLS 1391. 02. 05 2012. 04. 25 Babak_Valizadeh@hotmail.com Biological Safety Cabinet Process specimens in biological
More informationFor use with Sofia only
For use with Sofia only INTENDED USE The Sofia S. pneumoniae FIA employs immunofluorescence for qualitative detection of Streptococcus pneumoniae antigen in urine specimens of patients with pneumonia and
More informationClient Services M anual
Diagnostic Innovation Improving Health Client Services M anual [ Revised 09.27.18 ] Table of Contents About / Instructions Directory...2 About Diatherix...3 Specimen Preparation Instructions...4 Packaging
More informationDISEASE OUTBREAKS SUMMARY
DISEASE OUTBREAKS SUMMARY Outbreaks may be defined as (a) clusters of cases related in time and place or (b) occurrence of disease above a baseline or threshold level in a defined location. In Los Angeles
More informationIssued by: LABORATORY MANAGER Original Date: June 18, 2001 Approved by: Laboratory Director RESIDENT OBJECTIVES AT MSH
Policy # MI/EDU/08/04/v01 Page1 of 13 Section: Subject Title: Resident Objectives at MSH Issued by: LABORATORY MANAGER Original Date: June 18, 2001 Approved by: Laboratory Director Revision Date: SPECIMENS
More information